FORT WORTH, Texas--(BUSINESS WIRE)--March 3, 2006--Alcon, Inc. (NYSE:ACL) announced the withdrawal of its European marketing authorization application (MAA) for RETAANE(R) 30mg/ml (anecortave acetate suspension for depot injection) from The European Medicines Agency (EMEA) review process. The company chose to withdraw the application after being informed by EMEA that it would have to provide additional clinical data from existing and/or new clinical trials to support approval. The U.S. Food and Drug Administration (FDA) also recently advised the company that additional clinical data will be required for U.S. approval.
